Cosmos Health director awarded 20,000 shares

Cosmos Health Inc. director Karkantzos Theodoros Christos received an award of 20,000 shares of Common Stock at $0.283 per share under the company’s 2024 & 2025 Omnibus Incentive Plan.

Rhea-AI Filing Summary

Cosmos Health Inc. director Karkantzos Theodoros Christos received an award of 20,000 shares of Common Stock at $0.283 per share under the company’s 2024 & 2025 Omnibus Incentive Plan. A related Restricted Stock Unit grant converted, leaving him with 35,000 common shares held directly after these compensation transactions, and no remaining RSUs.

Insider Trade Summary

35,000 shares exercised/converted

Exercise 2 txns

Insider Karkantzos Theodoros Christos

Role Director

Type	Security	Shares	Price	Value
Conversion	Restricted Stock Unit	35,000	$0.00	$0.00
Grant/Award	Common Stock, par value $.001	20,000	$0.283	$6K

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock, par value $.001 — 35,000 shares (Direct)

Footnotes (2)

1. F1. Reflects the award of 20,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.
2. F2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

Key Figures

Stock award: 20,000 shares Award price: $0.283 per share Shares after transaction: 35,000 shares +2 more

5 metrics

Stock award 20,000 shares Common Stock grant under 2024 & 2025 Omnibus Incentive Plan

Award price $0.283 per share Reference price for 20,000-share Common Stock award

Shares after transaction 35,000 shares Total Common Stock directly held after Form 4 transactions

RSU transaction size 35,000 units Restricted Stock Unit derivative transaction recorded in Form 4

RSU conversion price $0.00 Conversion price for Restricted Stock Unit derivative security

Key Terms

Omnibus Incentive Plan, Restricted Stock Unit, RSUs, Rule 16b-3

4 terms

Omnibus Incentive Plan financial

"pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3."

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

Restricted Stock Unit financial

"The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSUs financial

"The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3."

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cosmos Health (COSM) report for Karkantzos Theodoros Christos?

Cosmos Health reported that director Karkantzos Theodoros Christos received an award of 20,000 shares of Common Stock as compensation. The shares were granted under the 2024 & 2025 Omnibus Incentive Plan and are treated as an acquisition, not an open-market purchase.

How many Cosmos Health (COSM) shares does the director hold after this Form 4?

Following these transactions, the director directly holds 35,000 shares of Cosmos Health Common Stock. This total reflects the 20,000-share stock award and the effect of converting Restricted Stock Units, with the RSU position reduced to zero in this filing.

What was the price per share for the Cosmos Health (COSM) stock award?

The reported stock award to the director used a reference price of $0.283 per share for 20,000 Common Stock shares. This figure comes from the Form 4 transaction details and reflects the value used for the compensation grant under the incentive plan.

How were the Cosmos Health (COSM) Restricted Stock Units treated in this filing?

The filing shows a derivative transaction labeled as Restricted Stock Unit with a conversion price of $0.00. Footnotes explain the RSUs were granted and vested on May 19, 2026, under the 2024 & 2025 Omnibus Incentive Plan, then converted, leaving no remaining RSUs.

Is the Cosmos Health (COSM) director’s Form 4 transaction an open-market buy or a compensation grant?

The Form 4 classifies the transaction as a grant, award, or other acquisition under code A, not an open-market purchase. Footnotes specify it is an award of 20,000 shares under the 2024 & 2025 Omnibus Incentive Plan, exempt under Rule 16b-3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Karkantzos Theodoros Christos

(Last) (First) (Middle)

5 AG. GEORGIOU STR.

(Street)

PILEA THESSALONIKI TK57001

(City) (State) (Zip)

GREECE

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cosmos Health Inc. [ COSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $.001	05/19/2026	05/19/2026	A(1)		20,000	A	$0.283	35,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	05/19/2026	05/19/2026	C			35,000	05/19/2026	05/19/2036	Common Stock, par value $.001	2,000	$0	0	D

Explanation of Responses:

1. Reflects the award of 20,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.

2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

	/s/ Theodoros C. Karkantzos	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)